Stifel slashes price target on Evofem Biosciences Inc. [EVFM] – find out why.

Must read

Evofem Biosciences Inc. [NASDAQ: EVFM] closed the trading session at $0.86 on 05/28/21. The day’s price range saw the stock hit a low of $0.799, while the highest price level was $0.8698. The company report on May 25, 2021 that Evofem Biosciences to Present at LD Micro Invitational XI on Tuesday, June 8, 2021.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Evofem Biosciences, Inc., (NASDAQ: EVFM) announced that its CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on Tuesday, June 8, 2021 at 1:00 p.m. ET (10:00 a.m. PT).

Pelletier will provide an update on the commercialization of Evofem’s hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), the ongoing Phase 3 clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women, and other ongoing initiatives.

The stocks have a year to date performance of -64.32 percent and weekly performance of 2.78 percent. The stock has been moved at -61.95 percent over the last six months. The stock has performed -41.10 percent around the most recent 30 days and changed -77.60 percent over the most recent 3-months.

If compared to the average trading volume of 7.62M shares, EVFM reached to a volume of 19642770 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Evofem Biosciences Inc. [EVFM]:

Stifel have made an estimate for Evofem Biosciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 02, 2020. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on August 20, 2020, representing the official price target for Evofem Biosciences Inc. stock. Previously, the target price had yet another raise to $11, while Piper Sandler analysts kept a Overweight rating on EVFM stock.

The Average True Range (ATR) for Evofem Biosciences Inc. is set at 0.10, with the Price to Sales ratio for EVFM stock in the period of the last 12 months amounting to 51.87.

EVFM stock trade performance evaluation

Evofem Biosciences Inc. [EVFM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.78. With this latest performance, EVFM shares dropped by -41.10% in over the last four-week period, additionally sinking by -61.95% over the last 6 months – not to mention a drop of -84.25% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVFM stock in for the last two-week period is set at 27.70, with the RSI for the last a single of trading hit 29.19, and the three-weeks RSI is set at 29.48 for Evofem Biosciences Inc. [EVFM]. The present Moving Average for the last 50 days of trading for this stock 1.49, while it was recorded at 0.82 for the last single week of trading, and 2.45 for the last 200 days.

Evofem Biosciences Inc. [EVFM]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Evofem Biosciences Inc. [EVFM] shares currently have an operating margin of -23234.08 and a Gross Margin at -269.73. Evofem Biosciences Inc.’s Net Margin is presently recorded at -31907.85.

Return on Total Capital for EVFM is now -200.98, given the latest momentum, and Return on Invested Capital for the company is -590.20. Return on Equity for this stock declined to -1,675.90, with Return on Assets sitting at -205.85. When it comes to the capital structure of this company, Evofem Biosciences Inc. [EVFM] has a Total Debt to Total Equity ratio set at 6,380.10. Additionally, EVFM Total Debt to Total Capital is recorded at 98.46, with Total Debt to Total Assets ending up at 78.15. Long-Term Debt to Equity for the company is recorded at 2,319.30, with the Long-Term Debt to Total Capital now at 35.79.

Reflecting on the efficiency of the workforce at the company, Evofem Biosciences Inc. [EVFM] managed to generate an average of -$968,088 per employee. Receivables Turnover for the company is 0.45 with a Total Asset Turnover recorded at a value of 0.01.Evofem Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.10.

Earnings per share (EPS) analysis for Evofem Biosciences Inc. [EVFM] stock

With the latest financial reports released by the company, Evofem Biosciences Inc. posted -0.91/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -145.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EVFM.

Evofem Biosciences Inc. [EVFM]: Insider Ownership positions

There are presently around $37 million, or 41.60% of EVFM stock, in the hands of institutional investors. The top three institutional holders of EVFM stocks are: INVESCO LTD. with ownership of 9,293,989, which is approximately -26.815% of the company’s market cap and around 2.20% of the total institutional ownership; BLACKROCK INC., holding 5,607,803 shares of the stock with an approximate value of $4.82 million in EVFM stocks shares; and VANGUARD GROUP INC, currently with $3.58 million in EVFM stock with ownership of nearly 15.801% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Evofem Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 64 institutional holders increased their position in Evofem Biosciences Inc. [NASDAQ:EVFM] by around 13,880,140 shares. Additionally, 42 investors decreased positions by around 4,477,749 shares, while 21 investors held positions by with 24,341,875 shares. The mentioned changes placed institutional holdings at 42,699,764 shares, according to the latest SEC report filing. EVFM stock had 33 new institutional investments in for a total of 8,614,782 shares, while 19 institutional investors sold positions of 732,020 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam